News & Updates
Filter by Specialty:
Ixazomib dexamethasone a new treatment in the arsenal against RRMM
In heavily pretreated, lenalidomide-refractory patients with relapsed-refractory multiple myeloma (RRMM) and prior exposure to proteasome inhibitors, ixazomib dexamethasone may be an effective and tolerable treatment approach, leading to comparable health-related quality of life outcomes as pomalidomide-dexamethasone, a recent study has found.
Ixazomib dexamethasone a new treatment in the arsenal against RRMM
18 Feb 2022
Patient-reported outcomes tied to healthcare use in NDMM
Patient-reported outcome measures may help predict healthcare utilization, such as emergency department visits or unplanned hospitalizations, among patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), a recent study has found.
Patient-reported outcomes tied to healthcare use in NDMM
16 Feb 2022
Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
CT-P6, a trastuzumab biosimilar approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), is as efficacious as reference trastuzumab in terms of response rates, progression-free (PFS) and overall survival (OS), a study has shown.
Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
16 Feb 2022
FOLFIRINOX safe, effective in older adults with advanced pancreatic cancer
The combination therapy of 5-fluorouracil, irinotecan, leucovorin, and oxaliplatin (FOLFIRINOX) improves response and overall survival (OS) in older adults with advanced pancreatic cancer (APC), a recent study has shown.
FOLFIRINOX safe, effective in older adults with advanced pancreatic cancer
14 Feb 2022
East Asia tops global lung cancer incidence and mortality
East Asia topped the world’s incidence and mortality of lung cancer in 2020, according to a global study conducted by the Chinese University of Hong Kong (CUHK) and the Association of Pacific Rim Universities (APRU).
